Literature DB >> 9308730

Mucin antigen expression in gastric carcinomas of young and old adults.

H Sakamoto1, S Yonezawa, T Utsunomiya, S Tanaka, Y S Kim, E Sato.   

Abstract

The striking differences in the histological features of gastric cancers in young and old adults have been thought to be related to differences in the biological behavior of these cancers. Recently, a new grading system (Goseki's classification) showed that the prognosis of the patient is particularly related to the mucin content of the carcinoma. In this study, we examined differences in mucin antigen expression in cancers from young and old adults and whether antigen expression is related to the clinical outcome. The expression of two mucin core proteins (DF3 antigen [MUC1 gene product] and MRP antigen [MUC2 gene product] and a mucin-type carbohydrate antigen [sialosyl-Tn; STn]) was examined immunohistochemically in gastric cancers from 69 young adults (30 to 39 years of age) and 110 old adults (80 to 89 years of age). The incidence rates of the three histological types (tubular adenocarcinoma, poorly differentiated adenocarcinoma, and signet-ring cell carcinoma) were different in the young and old adults. However, among the mucin antigens examined, only DF3 showed significantly higher frequency of expression in the old adults, and the difference was seen only in tubular adenocarcinomas (young, 43%; old, 68%) and poorly differentiated adenocarcinomas (young, 19%; old, 49%). In these two histological types, there was no difference in the frequency of MRP or STn expression between the young and old adults, although the old adults showed a high incidence of intestinal metaplasia that was positive for both antigens. Signet-ring cell carcinomas showed no significant difference in expression rates of the three antigens in young and old adults, but there were significantly higher expression rates in young patients for both MRP (young, 67%; old, 65%) and STn (young, 71%; old, 57%) and a lower rate of DF3 expression (young, 0%; old, 14%). In both young and old adults, the patients with DF3-positive carcinomas showed significantly poorer survival than those without DF3 expression, whereas there was not significant difference in the survival of the patient groups with positive and negative MRP or STn reactivity. In conclusion, the expression of DF3 was influenced by the age of patients and was related to the outcome. In contrast, MRP and STn expression was related more to the histological pattern of the tumor than to the age of the patient and did not correlate with the outcome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9308730     DOI: 10.1016/s0046-8177(97)90059-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

Review 1.  Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease.

Authors:  A P Corfield; N Myerscough; R Longman; P Sylvester; S Arul; M Pignatelli
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

2.  Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome.

Authors:  Elaine Cristina Morari; Joyce Rosário Silva; Ana Carolina Trindade Guilhen; Lucas Leite Cunha; Marjory Alana Marcello; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Endocr Pathol       Date:  2010-12       Impact factor: 3.943

3.  Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue.

Authors:  Shi-Fang Yuan; Kai-Zong Li; Ling Wang; Ke-Feng Dou; Zhen Yan; Wei Han; Ying-Qi Zhang
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

4.  Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis.

Authors:  Kristina Roessler; Stefan-P Mönig; Paul-M Schneider; Franz-Georg Hanisch; Stephanie Landsberg; Juergen Thiele; Arnulf-H Hölscher; Hans-P Dienes; Stephan-E Baldus
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

5.  MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma.

Authors:  Chanchai Boonla; Banchob Sripa; Peti Thuwajit; Ubon Cha-On; Anucha Puapairoj; Masanao Miwa; Sopit Wongkham
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

6.  Gastric and intestinal phenotypic cell marker expressions in gastric differentiated-type carcinomas: association with E-cadherin expression and chromosomal changes.

Authors:  Koji Morohara; Yusuke Tajima; Kentaro Nakao; Nobukazu Nishino; Shigeo Aoki; Masanori Kato; Masaaki Sakamoto; Kimiyasu Yamazaki; Tsutomu Kaetsu; Satoshi Suzuki; Akira Tsunoda; Tetsuhiko Tachikawa; Mitsuo Kusano
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-31       Impact factor: 4.553

7.  Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features.

Authors:  R-Q Wang; D-C Fang
Journal:  J Clin Pathol       Date:  2003-05       Impact factor: 3.411

8.  Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil.

Authors:  Yusuke Tajima; Tadakazu Shimoda; Yukihiro Nakanishi; Noboru Yokoyama; Takayuki Tanaka; Kouji Shimizu; Toyohiko Saito; Masatoshi Kawamura; Mitsuo Kusano; Kazuhide Kumagai
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-24       Impact factor: 4.553

9.  MUC5B expression in gastric carcinoma: relationship with clinico-pathological parameters and with expression of mucins MUC1, MUC2, MUC5AC and MUC6.

Authors:  J Pinto-de-Sousa; C A Reis; L David; A Pimenta; M Cardoso-de-Oliveira
Journal:  Virchows Arch       Date:  2004-01-31       Impact factor: 4.064

10.  Prognostic value of Goseki histological classification in adenocarcinoma of the cardia.

Authors:  M G Fontana; M La Pinta; D Moneghini; V Villanacci; F Donato; G Rindi; S Paparini; C Baronchelli; G Bertoli; P Alquati
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.